Brexit wasting time and money, say Welsh pharma companiesDrug companies in Wales have said that Brexit is wasting time and money that could be otherwise spent Share XBrexit wasting time and money, say Welsh pharma companieshttps://pharmaphorum.com/news/brexit-wasting-time-and-money-say-welsh-pharma-companies/
Takeda hurries $62bn Shire acquisition, calls investor vote next monthTakeda will hold an investor vote on its $62 billion acquisition of Shire next month, and aims to Share XTakeda hurries $62bn Shire acquisition, calls investor vote next monthhttps://pharmaphorum.com/news/takeda-hurries-62bn-shire-acquisition-calls-investor-vote-next-month/
US regulator grants fast review for AZ ovarian cancer drugThe US Food and Drug Administration (FDA) has granted AstraZeneca priority review for its ovarian cancer drug Lynparza Share XUS regulator grants fast review for AZ ovarian cancer drughttps://pharmaphorum.com/news/us-regulator-grants-fast-review-for-az-ovarian-cancer-drug/
Australians need more time to opt-out of My Health Record, say politiciansAustralia’s Senate has passed a motion calling on the government to extend an opt-out period for its controversial Share XAustralians need more time to opt-out of My Health Record, say politicianshttps://pharmaphorum.com/news/australians-need-more-time-to-opt-out-of-my-health-record-say-politicians/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
Vertex told to reveal CF drug price, as MPs begin inquiryUK politicians could go public with the price of Vertex’s cystic fibrosis drug Orkambi, if the company does Share XVertex told to reveal CF drug price, as MPs begin inquiryhttps://pharmaphorum.com/news/vertex-told-to-reveal-cf-drug-price-as-mps-begin/
Diabetes drugs cost NHS more than £1bn a yearDiabetes prescriptions are costing the NHS in England more than £1 billion a year, driven by an increase Share XDiabetes drugs cost NHS more than £1bn a yearhttps://pharmaphorum.com/news/diabetes-drugs-cost-nhs-more-than-1bn-a-year/
NICE rejects AZ’s Lynparza tablets in ovarian cancer maintenanceAstraZeneca has said it will continue pricing negotiations with the NHS and NICE after the cost-effectiveness body said Share XNICE rejects AZ’s Lynparza tablets in ovarian cancer maintenancehttps://pharmaphorum.com/news/nice-rejects-azs-lynparza-tablets-in-ovarian-cancer-maintenance/
China’s BeiGene delays US filing for rival to ImbruvicaBeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s Share XChina’s BeiGene delays US filing for rival to Imbruvicahttps://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/
